PMID- 24895099
OWN - NLM
STAT- MEDLINE
DCOM- 20160427
LR  - 20210504
IS  - 2327-6924 (Electronic)
IS  - 2327-6886 (Linking)
VI  - 26
IP  - 7
DP  - 2014 Jul
TI  - Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of 
      type 2 diabetes mellitus.
PG  - 356-63
LID - 10.1002/2327-6924.12135 [doi]
AB  - PURPOSE: The purpose of this article is to educate nurse practitioners about the 
      newest class of oral medications developed to treat type 2 diabetes mellitus 
      (T2DM). This article will review dapagliflozin and canagliflozin, the two Food 
      and Drug Administration (FDA) approved sodium glucose co-transporter 2 (SGLT2) 
      inhibitors, and discuss their place in therapy. DATA SOURCES: A comprehensive 
      literature search was conducted using MEDLINE with the key terms: dapagliflozin, 
      canagliflozin, SGLT2 inhibitors, and SGLT2 inhibitors. Other resources included 
      the World Health Organization (WHO), U.S. FDA, Centers for Disease Control and 
      Prevention (CDC), clinical guidelines, FDA labeling, briefings, and press 
      releases. CONCLUSIONS: Dapagliflozin and canagliflozin appear to be safe and 
      moderately effective. SGLT2 inhibitors provide an alternative for dual and triple 
      therapy for T2DM or can be used as monotherapy in patients who cannot tolerate 
      other first-line options. IMPLICATIONS FOR PRACTICE: SGLT2 inhibitors have a 
      unique, insulin-independent mechanism of action, targeting the kidneys. They have 
      a low incidence of hypoglycemia and result in a moderate reduction in HbA1C. 
      Improvements in weight, blood pressure, and lipid parameters have been 
      demonstrated. Dosing considerations are required for the elderly, renally 
      impaired, and patients at risk for hypotension.
CI  - (c)2014 American Association of Nurse Practitioners.
FAU - Davis, Courtney S
AU  - Davis CS
AD  - Department of Pharmacy Practice, University of Mississippi School of Pharmacy, 
      Jackson, Mississippi.
FAU - Fleming, Joshua W
AU  - Fleming JW
FAU - Warrington, Laurie E
AU  - Warrington LE
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140604
PL  - United States
TA  - J Am Assoc Nurse Pract
JT  - Journal of the American Association of Nurse Practitioners
JID - 101600770
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
MH  - Benzhydryl Compounds/pharmacology/therapeutic use
MH  - Canagliflozin/pharmacology/therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Disease Management
MH  - Glucosides/pharmacology/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Sodium-Glucose Transporter 2/adverse effects/pharmacology/*therapeutic use
MH  - United States
OTO - NOTNLM
OT  - Dapagliflozin
OT  - SGLT2 inhibitors
OT  - canagliflozin
OT  - sodium glucose co-transporter 2 inhibitors
EDAT- 2014/06/05 06:00
MHDA- 2016/04/28 06:00
CRDT- 2014/06/05 06:00
PHST- 2014/06/05 06:00 [entrez]
PHST- 2014/06/05 06:00 [pubmed]
PHST- 2016/04/28 06:00 [medline]
AID - 10.1002/2327-6924.12135 [doi]
PST - ppublish
SO  - J Am Assoc Nurse Pract. 2014 Jul;26(7):356-63. doi: 10.1002/2327-6924.12135. Epub 
      2014 Jun 4.